4
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
8
Rare Diseases
across 11 areas
0
News (30d)
Quiet
Pyxis Oncology, Inc. is a company with 4 orphan drug designations across 8 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Smith-Lemli-Opitz syndrome | sotigalimab | Des.TrialAppr. |
| esophageal atresia | sotigalimab | Des.TrialAppr. |
| esophageal atresia/tracheoesophageal fistula | sotigalimab | Des.TrialAppr. |
| esophageal cancer | sotigalimab | Des.TrialAppr. |
| esophageal duplication cyst | sotigalimab | Des.TrialAppr. |
| esophageal tuberculosis | sotigalimab | Des.TrialAppr. |
| malignant pancreatic neoplasm | multi-species cross-reactive anti-extra domain-B splice variant of fibronectin (EDB+FN) fully human IgG1 antibody engineered with 4 reactive cysteines to enable site-specific conjugation (kC183 + C290) to 4 Auristatin010sotigalimab | Des.TrialAppr. |
| soft tissue sarcoma | sotigalimab | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
22
overlap in 2+ diseases
0/8
candidate diseases
0
avg importance: 0
0
affecting portfolio